PL3007682T3 - Formulacja o modyfikowanym uwalnianiu - Google Patents
Formulacja o modyfikowanym uwalnianiuInfo
- Publication number
- PL3007682T3 PL3007682T3 PL14741382T PL14741382T PL3007682T3 PL 3007682 T3 PL3007682 T3 PL 3007682T3 PL 14741382 T PL14741382 T PL 14741382T PL 14741382 T PL14741382 T PL 14741382T PL 3007682 T3 PL3007682 T3 PL 3007682T3
- Authority
- PL
- Poland
- Prior art keywords
- release formulation
- modified release
- modified
- formulation
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361834104P | 2013-06-12 | 2013-06-12 | |
PCT/IB2014/062136 WO2014199316A1 (en) | 2013-06-12 | 2014-06-11 | Modified release formulation |
EP14741382.7A EP3007682B1 (en) | 2013-06-12 | 2014-06-11 | Modified release formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3007682T3 true PL3007682T3 (pl) | 2017-12-29 |
Family
ID=51211272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14741382T PL3007682T3 (pl) | 2013-06-12 | 2014-06-11 | Formulacja o modyfikowanym uwalnianiu |
Country Status (22)
Country | Link |
---|---|
US (3) | US20160128979A1 (pl) |
EP (1) | EP3007682B1 (pl) |
JP (1) | JP6444996B2 (pl) |
KR (1) | KR102290249B1 (pl) |
CN (2) | CN111467313A (pl) |
AU (1) | AU2014279743B2 (pl) |
BR (1) | BR112015030431B1 (pl) |
CA (1) | CA2911486C (pl) |
CL (1) | CL2015003596A1 (pl) |
EA (1) | EA031395B1 (pl) |
ES (1) | ES2644698T3 (pl) |
HK (1) | HK1216839A1 (pl) |
MA (1) | MA38646B1 (pl) |
MX (1) | MX369742B (pl) |
PE (1) | PE20160183A1 (pl) |
PH (1) | PH12015502556A1 (pl) |
PL (1) | PL3007682T3 (pl) |
PT (1) | PT3007682T (pl) |
SG (1) | SG11201509178TA (pl) |
TN (1) | TN2015000498A1 (pl) |
WO (1) | WO2014199316A1 (pl) |
ZA (1) | ZA201508228B (pl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016328150B2 (en) | 2015-09-23 | 2020-10-01 | Xw Laboratories Inc. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
WO2019025932A1 (en) * | 2017-07-31 | 2019-02-07 | Novartis Ag | USE OF MUSSELUROUS IN REDUCING THE USE OF ALCOHOL OR IN THE PREVENTION OF RECHUTE IN THE USE OF ALCOHOL |
CN110958879A (zh) * | 2017-07-31 | 2020-04-03 | 诺华股份有限公司 | 玛沃谷兰在减少***使用或预防复用***中的用途 |
EP3917518A1 (en) | 2019-01-29 | 2021-12-08 | Novartis AG | The use of an mglur5 antagonist for treating opioid analgesic tolerance |
CA3181961A1 (en) | 2020-07-17 | 2022-01-20 | Novartis Ag | Use of mglur5 antagonists |
WO2022123482A1 (en) | 2020-12-11 | 2022-06-16 | Novartis Ag | Use of mglur5 antagonists for treating amphetamine addiction |
CA3204360A1 (en) | 2020-12-14 | 2022-06-23 | Novartis Ag | Use of mglur5 antagonists for treating gambling disorder |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
EP1660313A1 (en) * | 2003-08-25 | 2006-05-31 | Alpex Pharma SA | Tablet punches and method for tableting |
GB0514296D0 (en) * | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
JP2009516707A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 固形製剤 |
US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
US20080085305A1 (en) | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations of oxymorphone |
NZ577560A (en) | 2007-01-16 | 2012-01-12 | Egalet Ltd | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
US9173864B2 (en) * | 2008-10-22 | 2015-11-03 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
US20120039999A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
AR084515A1 (es) * | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
WO2012139876A1 (en) * | 2011-04-14 | 2012-10-18 | Merz Pharma Gmbh & Co. Kgaa | Enteric formulations of metabotropic glutamate receptor modulators |
-
2014
- 2014-06-11 SG SG11201509178TA patent/SG11201509178TA/en unknown
- 2014-06-11 CA CA2911486A patent/CA2911486C/en active Active
- 2014-06-11 MX MX2015017202A patent/MX369742B/es active IP Right Grant
- 2014-06-11 AU AU2014279743A patent/AU2014279743B2/en active Active
- 2014-06-11 PT PT147413827T patent/PT3007682T/pt unknown
- 2014-06-11 CN CN202010410902.8A patent/CN111467313A/zh active Pending
- 2014-06-11 KR KR1020167000347A patent/KR102290249B1/ko active IP Right Grant
- 2014-06-11 ES ES14741382.7T patent/ES2644698T3/es active Active
- 2014-06-11 MA MA38646A patent/MA38646B1/fr unknown
- 2014-06-11 WO PCT/IB2014/062136 patent/WO2014199316A1/en active Application Filing
- 2014-06-11 EP EP14741382.7A patent/EP3007682B1/en active Active
- 2014-06-11 CN CN201480031900.0A patent/CN105263479A/zh active Pending
- 2014-06-11 US US14/897,439 patent/US20160128979A1/en not_active Abandoned
- 2014-06-11 PL PL14741382T patent/PL3007682T3/pl unknown
- 2014-06-11 JP JP2016518626A patent/JP6444996B2/ja active Active
- 2014-06-11 TN TN2015000498A patent/TN2015000498A1/en unknown
- 2014-06-11 EA EA201690005A patent/EA031395B1/ru not_active IP Right Cessation
- 2014-06-11 PE PE2015002586A patent/PE20160183A1/es not_active Application Discontinuation
- 2014-06-11 BR BR112015030431-1A patent/BR112015030431B1/pt active IP Right Grant
-
2015
- 2015-11-06 ZA ZA2015/08228A patent/ZA201508228B/en unknown
- 2015-11-10 PH PH12015502556A patent/PH12015502556A1/en unknown
- 2015-12-11 CL CL2015003596A patent/CL2015003596A1/es unknown
-
2016
- 2016-04-20 HK HK16104528.5A patent/HK1216839A1/zh unknown
-
2020
- 2020-06-10 US US16/898,071 patent/US20210069150A1/en active Pending
-
2023
- 2023-07-20 US US18/355,618 patent/US20230355582A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279395A (en) | A vaccine | |
EP3065716C0 (en) | FORMULATIONS | |
EP2955024A4 (en) | ANTI-ADHERENT FILM | |
GB201318403D0 (en) | Release mechanism | |
EP3006525A4 (en) | ASPHALT-URETHANE COMPOSITION | |
GB201319792D0 (en) | Formulations | |
HK1216839A1 (zh) | 調整釋放製劑 | |
EP2961397A4 (en) | TRANSDERMAL FORMULATIONS | |
GB201317388D0 (en) | Composition | |
GB201415924D0 (en) | Load release means | |
HK1224228A1 (zh) | 新型製劑 | |
HK1214951A1 (zh) | 眼用製劑 | |
EP3066178A4 (en) | GREASE COMPOSITION | |
GB201320432D0 (en) | Novel formulation | |
GB201306984D0 (en) | Composition | |
GB201317196D0 (en) | Composition | |
GB201307622D0 (en) | Composition | |
GB201322948D0 (en) | Improved formulation | |
GB201308502D0 (en) | Composition | |
GB201301774D0 (en) | Composition | |
GB2517232B (en) | Formulation | |
GB201317718D0 (en) | Novel formulation | |
GB201318394D0 (en) | Composition | |
EP3037100A4 (en) | MEANS TO PREVENT MUSCLE ATROPHY | |
GB201305622D0 (en) | Composition |